The Precision
Oncology Company
About us
The Precision
Oncology Company
PANGAEA ONCOLOGY is a company focused on Precision Oncology, which offers both patients and pharmaceutical companies different services with the aim of improving the survival of cancer patients, their response to treatments, and their quality of life.
PANGAEA ONCOLOGY IN FIGURES
PATIENTS
VISITS
ACTS
TRIALS
CLIENTS
(FTE)
OUR CORE COMMITMENTS
PANGAEA ONCOLOGY’s mission is to change the natural history of the disease, improving the survival of cancer patients, through the application of the best professionals and technologies.
Position PANGAEA ONCOLOGY as the reference in Southern Europe in Precision Oncology, from patient treatment, the provision of services to the industry, the incorporation of disruptive technology and medical-scientific excellence, and directed towards systems intelligent IT and data exploitation (IA/BIG DATA).
OUR SERVICES
Molecular diagnostics
Rapid, accurate diagnosis. Our comprehensive & highly sensitive & specific range of tests can detect genetic alterations that drive tumor growth in all types of cancer.
DX platforms Validation
Molecular companion diagnostics tests provide essential information that enables doctors to identify those patients that are most likely to benefit from a treatment.
Pre-clinical services:
The PANGAEA LAB team is composed of prestigious research professionals and combines expertise in preclinical cancer research with extensive experience in R&D diagnostics.
our latest news & publications
- All Post
- Instituto Oncológico Rosell
- Pangaea Oncology
- Quénet Torrent Institute
Pangaea Oncology boosts growth through small acquisitions in private healthcare. Take advantage of more personalized and less toxic drugs based on the genetic profiles of each patient.
We are pleased to share the success story of Anisha Jain, a PhD student from the JSS Medical Research, India. Thanks to EACR Travel Fellowship, join us at Instituto Oncológico Dr. Rosell.
The decision whether or not to add HIPEC to surgery in ovarian cancer recurrence is clear: intraoperative chemotherapy increases survival without added toxicity.